Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?

Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1

(2017) Katarzyna Guzik et al.   JOURNAL OF MEDICINAL CHEMISTRY

The immuno-oncology race: myths and emerging realities

(2017) Stephen Cavnar et al.   NATURE REVIEWS DRUG DISCOVERY

Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2

(2017) Krzysztof M. Zak et al.   STRUCTURE

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells

(2017) Lukasz Skalniak et al.   Oncotarget

Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy

(2017) Eszter Lázár-Molnár et al.   EBioMedicine

Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade

(2017) Fei Zhang et al.   Cell Discovery

Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies

(2016) Yi Xia et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy

(2016) Kefang Liu et al.   CELL RESEARCH

Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab

(2016) Zhenkun Na et al.   CELL RESEARCH

Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015)

(2016) Tryfon Zarganes-Tzitzikas et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

A case of fatal Guillain–Barre syndrome from anti-PD1 monoclonal antibody use

(2016) Aasems Jacob et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

(2016) Weijie Ma et al.   Journal of Hematology & Oncology

Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant

(2016) Roberta Pascolutti et al.   STRUCTURE

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

(2016) Ju Yeon Lee et al.   Nature Communications

Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)

(2016) Krzysztof M. Zak et al.   Oncotarget

High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1

(2016) Shoichiro Horita et al.   Scientific Reports

Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy

(2015) Xiangjiao Meng et al.   CANCER TREATMENT REVIEWS

Human PD-1 binds differently to its human ligands: A comprehensive modeling study

(2015) Clement Viricel et al.   JOURNAL OF MOLECULAR GRAPHICS & MODELLING

Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab

(2015) Giovanna Scapin et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1

(2015) Krzysztof M. Zak et al.   STRUCTURE

Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab

(2015) Giovanna Scapin et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

(2015) Luisa Carbognin et al.   PLoS One

Programmed Death-1: Therapeutic Success after More than 100 Years of Cancer Immunotherapy

(2014) Alexander Dömling et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Targeting Protein-Protein Interaction by Small Molecules

(2013) Lingyan Jin et al.   Annual Review of Pharmacology and Toxicology

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic antibodies: successes, limitations and hopes for the future

(2009) Patrick Chames et al.   BRITISH JOURNAL OF PHARMACOLOGY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

(2008) D. Y.-w. Lin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2

(2008) E. Lazar-Molnar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA